The Current Ratio as of November 2024 (TTM) for Reata Pharmaceuticals, Inc. (RETA) is 6.75

According to Reata Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current Current Ratio is 6.75. This represents a change of 8.70% compared to the average of 6.21 of the last 4 quarters.

Reata Pharmaceuticals, Inc. (RETA) Historical Current Ratio (quarterly & annually)

How has RETA Current Ratio performed in the past?

The mean historical Current Ratio of Reata Pharmaceuticals, Inc. over the last ten years is 4.35. The current 6.75 Current Ratio has changed 15.39% with respect to the historical average. Over the past ten years (40 quarters), RETA's Current Ratio was at its highest in in the June 2020 quarter at 13.57. The Current Ratio was at its lowest in in the June 2014 quarter at 0.

Reata Pharmaceuticals, Inc. (RETA) Current Ratio by Quarter and Year

Discovering the peaks and valleys of Reata Pharmaceuticals, Inc. Current Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Reata Pharmaceuticals, Inc. (RETA) Average Current Ratio

How has RETA Current Ratio performed in the past?

The current Current Ratio of Reata Pharmaceuticals, Inc. (RETA) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Reata Pharmaceuticals, Inc. (RETA) Current Ratio vs. Peers

How is RETA’s Current Ratio compared to its peers?

Reata Pharmaceuticals, Inc.’s Current Ratio is greater than Sarepta Therapeutics, Inc. (3.84), less than Mirati Therapeutics, Inc. (7.54), less than Krystal Biotech, Inc. (7.97), greater than Intercept Pharmaceuticals, Inc. (4.22), less than PTC Therapeutics, Inc. (0), greater than Madrigal Pharmaceuticals, Inc. (2.10), greater than CureVac N.V. (5.98), greater than Vir Biotechnology, Inc. (6.20), less than Propanc Biopharma, Inc. (8.94), greater than Viking Therapeutics, Inc. (0.01), less than Terns Pharmaceuticals, Inc. (36.47), less than Akero Therapeutics, Inc. (32.99), less than null (17.25),

Build a custom stock screener for Reata Pharmaceuticals, Inc. (RETA) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Reata Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Reata Pharmaceuticals, Inc. (RETA) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Reata Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.